

## *Shilpa Medicare Limited*

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Date: 14 October 2021

To  
Corporate Relationship Department  
BSE Limited,  
1<sup>st</sup> Floor, Rotunda Building,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001.

To  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051.

**Scrip Code:** 530549/ **Stock Symbol:** SHILPAMED

Dear Sir/Ma’am,

**Sub:** Media Release

In continuation to the outcome of the Board meeting provided today i.e., 14 October 2021 with regard to issue of 52.75 lacs equity shares on preferential basis to various marquee investors aggregating to Rs. 297.51 crores at a price of Rs. 564 per share, please find enclosed copy of Media Release.

Kindly take the same on record.

**For and on behalf of  
Shilpa Medicare Limited**

**V V Krishna Chaitanya  
Company Secretary & Compliance Officer**

## MEDIA RELEASE

# Shilpa Medicare raises over Rs. 297 crore from marquee investors

- *Reaffirms commitment to growth based on innovative products and strategies*
- *Equity raise to finance growth and investments in Biological space*

Raichur, October 14, 2021: The Board of Directors of Shilpa Medicare Limited (SML) at its meeting held today approved the preferential allotment of 52.75 lacs equity shares aggregating to Rs. 297.51 crores to various marquee investors at a price of Rs. 564 per share.

The marquee investors who participated in the fund raise include Malabar India Fund Limited, Malabar Select Fund, Malabar Midcap Fund, Think India Opportunities Master Fund LP, Blue Daimond Properties Private Limited, Ohm Core Investment Corp, Hypnos Fund Limited and Mr. Madhusudan Kela. The completion of the transaction is subject to necessary shareholder & other regulatory approvals.

The fund raising will enable the company to leverage growth opportunities in identified niche areas including Biosimilars and New Biological Entity space. The levered position created by continuous growth investments made by the Company in the recent past also gets addressed through this equity infusion.

Speaking on the occasion, **Mr. Vishnukant Bhutada, Managing Director** of the Company, shared, ***“We are extremely happy to welcome a new set of focused investors into the Company. I also take this opportunity to express gratitude to existing investors for the confidence and strong support that they have shown in us. This development will go a long way in strengthening SML’s balance sheet and providing impetus to future growth.”***

**DAM Capital Advisors Limited (Formerly IDFC Securities Limited)** acted as the exclusive Financial Advisor to the Company. DAM Capital Advisors is an integrated full-service Investment Bank including an Institutional Equities platform and Mergers and Acquisitions Advisory. The company is owned and led by veteran deal maker, Mr. Dharmesh Mehta, who has more than 30 years of experience in the capital markets.

### **About Shilpa Medicare Limited**

Shilpa Medicare Limited (SML) is engaged in manufacturing and sale of affordable API and Formulations in various markets around the world. Currently it is one of the leaders in the oncology market and offers a complete range of products in the segment backed by strong R&D and manufacturing capabilities. Further to consolidate in field of oncology, SML has also made investments in the field of novel drug delivery systems and biotech products along with widening focus to other therapeutic areas.

SML, through its subsidiary Shilpa Biologics, has developed a novel biologics media manufacturing platform with complete backward integration. This is likely to position the Company as one of the lowest cost player in the biologics market with significant competitive moat. Shilpa Biologics has developed capabilities for production of MABS, vaccines and other recombinant proteins from mammalian cells combined with robotic filling lines for pre-filled syringes and vials. The biosimilar pipeline of the company includes 6 of the top 20 biological products in the World and it has developed 1 new biological entity with granted technology patent in the US & European markets.

*For more information, please contact:*

**Siddharth Rangnekar**  
**CDR India**

Tel: +91 22 6645 1209 / 1220  
siddharth@cdr-india.com